Literature DB >> 24120591

Hypoxia-inducible factor-1α(Pro-582-Ser) polymorphism prevents iron deprivation in healthy blood donors.

Lorenza Torti1, Luciana Teofili2, Sara Capodimonti2, Eugenia R Nuzzolo2, Maria Grazia Iachininoto2, Giuseppina Massini2, Serelina Coluzzi3, Agostino Tafuri3, Francesco Fiorin4, Gabriella Girelli3, Gina Zini2, Luigi M Larocca5.   

Abstract

BACKGROUND: Frequent blood loss induces progressive depletion of iron stores, leading to iron deficiency and, ultimately, to overt iron-deficient anaemia. The erythropoietin-mediated bone marrow response to anaemia is under the control of hypoxia-inducible factors (HIF), the master regulators of oxygen and iron homeostasis. Since the HIF-1α(Pro-582-Ser) variant is associated with elevated trans-activation capacity of hypoxia responsive elements of target genes, we investigated whether the HIF-1α(Pro-582-Ser) polymorphism might influence the response to repeated blood withdrawals.
MATERIALS AND METHODS: Using polymerase chain reaction analysis and DNA sequencing, we retrospectively investigated the presence of HIF-1α(Pro-582-Ser) in a series of 163 blood donors. Haematological findings, serum ferritin levels and frequency of donations were compared according to the mutational status of the HIF-1α gene.
RESULTS: We found that male carriers of the HIF-1α(Pro-582-Ser) polymorphism had higher haemoglobin and ferritin levels than individuals homozygous for the wild-type allele. Moreover, the HIF-1α(Pro-582-Ser) polymorphism protected regular blood donors from developing iron deficiency and anaemia and predicted uninterrupted donation activity. DISCUSSION: These findings show for the first time that the HIF-1α(Pro-582-Ser) polymorphism significantly affects red blood cell and iron homeostasis after blood loss, conferring to male carriers a resistance to anaemia. Regarding the female gender, large series of individuals should be investigated to establish whether there is an effect of the HIF-1α(Pro-582-Ser) polymorphism in this population. Although these data need to be confirmed in prospective studies, they could have important implications in blood donor selection and donation procedures.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24120591      PMCID: PMC3827400          DOI: 10.2450/2013.0076-13

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  15 in total

1.  Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome.

Authors:  Fiorina Giona; Luciana Teofili; Maria Luisa Moleti; Maurizio Martini; Giovanna Palumbo; Angela Amendola; Maria Gabriella Mazzucconi; Anna Maria Testi; Patrizia Pignoloni; Sonia Maria Orlando; Sara Capodimonti; Mauro Nanni; Giuseppe Leone; Luigi Maria Larocca; Robin Foà
Journal:  Blood       Date:  2012-01-18       Impact factor: 22.113

2.  The heterozygote advantage of the Chuvash polycythemia VHLR200W mutation may be protection against anemia.

Authors:  Galina Y Miasnikova; Adelina I Sergueeva; Mehdi Nouraie; Xiaomei Niu; Daniel J Okhotin; Lydia A Polyakova; Tomas Ganz; Josef T Prchal; Victor R Gordeuk
Journal:  Haematologica       Date:  2011-05-23       Impact factor: 9.941

3.  The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.

Authors:  S C Clifford; D Astuti; L Hooper; P H Maxwell; P J Ratcliffe; E R Maher
Journal:  Oncogene       Date:  2001-08-16       Impact factor: 9.867

4.  Testosterone replacement therapy promotes angiogenesis after acute myocardial infarction by enhancing expression of cytokines HIF-1a, SDF-1a and VEGF.

Authors:  Yeping Chen; Lu Fu; Ying Han; Yueqiu Teng; Junfeng Sun; Rongsheng Xie; Junxian Cao
Journal:  Eur J Pharmacol       Date:  2012-03-30       Impact factor: 4.432

Review 5.  Congenital polycythemias/erythrocytoses.

Authors:  Victor R Gordeuk; David W Stockton; Josef T Prchal
Journal:  Haematologica       Date:  2005-01       Impact factor: 9.941

6.  Sequence variation in hypoxia-inducible factor 1alpha (HIF1A): association with maximal oxygen consumption.

Authors:  Steven J Prior; James M Hagberg; Dana A Phares; Michael D Brown; Liane Fairfull; Robert E Ferrell; Stephen M Roth
Journal:  Physiol Genomics       Date:  2003-09-29       Impact factor: 3.107

7.  Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance.

Authors:  Keiji Tanimoto; Koji Yoshiga; Hidetaka Eguchi; Mika Kaneyasu; Kei Ukon; Tsutomu Kumazaki; Naohide Oue; Wataru Yasui; Kazue Imai; Kei Nakachi; Lorenz Poellinger; Masahiko Nishiyama
Journal:  Carcinogenesis       Date:  2003-08-14       Impact factor: 4.944

8.  Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Authors:  Luciana Teofili; Fiorina Giona; Maurizio Martini; Tonia Cenci; Francesco Guidi; Lorenza Torti; Giovanna Palumbo; Angela Amendola; Robin Foà; Luigi M Larocca
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

Review 9.  HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression.

Authors:  Brian Keith; Randall S Johnson; M Celeste Simon
Journal:  Nat Rev Cancer       Date:  2011-12-15       Impact factor: 60.716

10.  A common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1alpha (HIF-1alpha) does not impair Pro-564 hydroxylation.

Authors:  Melanie J Percy; Sharon M Mooney; Mary Frances McMullin; Adrian Flores; Terence R J Lappin; Frank S Lee
Journal:  Mol Cancer       Date:  2003-09-09       Impact factor: 27.401

View more
  3 in total

1.  Genetic factors associated with iron storage in Australian blood donors.

Authors:  Yu Ji; Robert Flower; Catherine Hyland; Nargess Saiepour; Helen Faddy
Journal:  Blood Transfus       Date:  2016-12-21       Impact factor: 3.443

2.  Integrative Map of HIF1A Regulatory Elements and Variations.

Authors:  Tanja Kunej
Journal:  Genes (Basel)       Date:  2021-09-28       Impact factor: 4.096

3.  NO ASSOCIATION BETWEEN tHbmass AND POLYMORPHISMS IN THE HBB GENE IN ENDURANCE ATHLETES.

Authors:  J Malczewska-Lenczowska; J Orysiak; E Majorczyk; A Pokrywka; J Kaczmarski; Z Szygula; D Sitkowski
Journal:  Biol Sport       Date:  2014-04-05       Impact factor: 2.806

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.